Compare
Vistagen Therapeutics, Inc. vs IGC Pharma, Inc. vs Longeveron Inc. vs Neuphoria Therapeutics Inc.
| Latest fiscal year | Vistagen Therapeutics, Inc. VTGN | IGC Pharma, Inc. IGC | Longeveron Inc. LGVN | Neuphoria Therapeutics Inc. NEUP |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-03-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $1.27M | $1.27M | $1.20M | $1.17M |
| Revenue growth (YoY) | +161.1% | -5.5% | -49.9% | -92.5% |
| Gross margin | n/a | 48.7% | 67.0% | n/a |
| Operating margin | n/m | -585.8% | n/m | n/m |
| Net margin | n/m | -560.3% | n/m | n/m |
| Net income | -$69.69M | -$7.12M | -$22.70M | -$13.45M |
| EPS (Diluted) | -$1.83 | -$0.09 | -$1.29 | -$3.06 |
| Operating cash flow | -$66.44M | -$4.79M | -$18.64M | -$12.35M |
| Free cash flow | n/a | -$4.91M | -$18.89M | n/a |
| Cash & equivalents | $30.79M | $405.0K | $4.66M | $19.87M |
| Total assets | $48.56M | $8.75M | $10.26M | $28.71M |
| Total liabilities | $13.04M | $2.42M | $4.59M | $4.11M |
| Shareholders' equity | $35.52M | $6.33M | $5.67M | $24.60M |
| Return on year-end equity | -196.2% | -112.5% | -400.1% | -54.7% |
| Shares outstanding | n/a | 80.88M | n/a | 5.41M |
Revenue, most recent five fiscal years
| Fiscal year | Vistagen Therapeutics, Inc. | IGC Pharma, Inc. | Longeveron Inc. | Neuphoria Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $1.27M Ended 2026-03-31 | $1.27M Ended 2025-03-31 | $1.20M Ended 2025-12-31 | $1.17M Ended 2026-06-30 |
| 1 year earlier | $486.0K Ended 2025-03-31 | $1.34M Ended 2024-03-31 | $2.39M Ended 2024-12-31 | $15.65M Ended 2025-06-30 |
| 2 years earlier | $1.06M Ended 2024-03-31 | $911.0K Ended 2023-03-31 | $709.0K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $397.0K Ended 2022-03-31 | $1.22M Ended 2022-12-31 | n/a |
| 4 years earlier | $1.11M Ended 2022-03-31 | $898.0K Ended 2021-03-31 | $1.31M Ended 2021-12-31 | n/a |